Obstetrics, Gynecology and Reproductive Biology Research
Polycystic Ovarian Syndrome Study
Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects with Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens
AGE: 18 – 40 years old
SEX AT BIRTH: Female
SEX AT BIRTH: Female
TYPE: Interventional Study
CONDITION: Polycystic Ovarian Syndrome (PCOS)
CONDITION: Polycystic Ovarian Syndrome (PCOS)
HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Cleveland Medical Center
LOCATION: University Hospitals Cleveland Medical Center
Learn More About This Research Study
For more information, please contact the study coordinator, Sarah Hornung at 216-983-0832 or complete the online form below.
Study Purpose
The purpose of this research study is to test the safety and behavior of an investigational drug, tildacerfont, in your body.
Who Can Participate
Female participants between 18 to 40 years of age with a confirmed diagnosis of PCOS may be eligible for this study.